Zydus receives tentative approval from the USFDA for Lorcaserin Hydrochloride Tablets

Zydus receives tentative approval from the USFDA for Lorcaserin Hydrochloride Tablets ______________________________________________________________ Ahmedabad, 3 December 2019 Zydus Cadila has received the tentative approval from the USFDA to market Lorcaserin Hydrochloride Tablets ( US RLD – Belviq Tablets ), 10 mg. The drug is used together with diet and exercise to treat obesity . It will be manufactured at the group’s formulations manufacturing facility at SEZ. The group now has 278 approvals and ha s so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare t herapies. The group employs nearly 25,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗